EPA-0682 – Investigator-rated symptomatological outcomes in a phase 4 study of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder and impaired executive function

Self-Reported quality of life in adults

Self-Reported quality of life in adults with attention-deficit/hyperactivity disorder and executive function impairment treated with lisdexamfetamine dimesylate: a randomized, double-blind, multicenter, placebo-controlled, parallel-group study

✍ Adler, Lenard A. (author);Dirks, Bryan (author);Deas, Patrick (author);Raychaudh 📂 Article 📅 2013 🏛 BioMed Central 🌐 English ⚖ 399 KB

Self-Reported quality of life in adults

Self-Reported quality of life in adults with attention-deficit/hyperactivity disorder and executive function impairment treated with lisdexamfetamine dimesylate: a randomized, double-blind, multicenter, placebo-controlled, parallel-group study

✍ Adler, Lenard A. (author);Dirks, Bryan (author);Deas, Patrick (author);Raychaudh 📂 Article 📅 2013 🏛 BioMed Central 🌐 English ⚖ 399 KB

Health-Related Quality of Life and Funct

✍ Tobias Banaschewski, César Soutullo, Michel Lecendreux, Mats Johnson… 📂 Article 📅 2013 🏛 Adis International Limited (now part of Wolters Kl 🌐 English ⚖ 536 KB

Psychiatric-related safety outcomes of l

✍ Lecendreux, M.L.; Dittmann, R.W.; Gasior, M.; Banaschewski, T.; Civil, R.; Bloom 📂 Article 📅 2012 🏛 Elsevier Science 🌐 French ⚖ 64 KB